Celcuity Inc. stocks have been trading up by 15.33 percent following highly positive news on its oncology pipeline progress.
Live Update At 11:32:00 EDT: On Monday, May 04, 2026 Celcuity Inc. stock [NASDAQ: CELC] is trending up by 15.33%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
CELC has turned into a momentum biotech name, and the tape shows it. Over the last dozen trading days, Celcuity Inc. has run from closes near $117–$120 up to $144.91 most recently. That’s a strong, steady uptrend with higher lows and mostly higher highs, not a one‑day fluke.
On 2026/05/04, CELC opened around $142.12, dipped hard to $136.06 at the open flush, then reclaimed and closed near the high of the day. That intraday reversal tells traders buyers are eager to step in on weakness. The 5‑minute chart around the $145 area shows tight trading, with CELC cycling between roughly $144.5 and $149.6. That kind of consolidation after a run usually signals active price discovery, not exhausted momentum.
Fundamentally, Celcuity Inc. is still a classic development‑stage biotech. The latest quarter shows about -$50.97M in net loss and negative free cash flow near -$36.45M. Returns on equity and assets are deeply negative, and CELC carries about $321.9M in long‑term debt. At the same time, Celcuity Inc. holds a large cash and investments cushion, with current assets around $465.66M and a strong current ratio of 10.6. For traders, that combo screams “high‑risk, catalyst‑driven story with runway,” not a steady earnings play.
Why Traders Are Watching CELC Right Now
CELC is on radar screens because the clinical and regulatory story just hit a new gear. Celcuity Inc. announced that its Phase 3 VIKTORIA‑1 trial in PIK3CA‑mutant HR+/HER2‑ metastatic breast cancer met its primary endpoint. Gedatolisib plus fulvestrant, with or without palbociclib, delivered statistically significant and clinically meaningful improvements in progression‑free survival versus alpelisib plus fulvestrant. For traders, that’s the kind of clean, binary readout that can reprice a biotech overnight.
The key here is not only that VIKTORIA‑1 hit. It’s that CELC is pairing strong efficacy with a “generally well‑tolerated” and “manageable” safety profile. Many oncology names stumble on toxicity once you get to Phase 3. Celcuity Inc. is signaling that gedatolisib held up under the pressure in both triplet and doublet regimens.
At the same time, Citizens has stepped in with fresh coverage, slapping an Outperform rating and a $150 price target on CELC. That target, anchored to gedatolisib’s potential, assumes value from both the PIK3CA‑mutant and wild‑type populations. The bank flagged the VIKTORIA‑1 data and an expected first approval in July for PIK3CA wild‑type patients as core drivers.
Layer on the existing Priority Review for gedatolisib in the wild‑type setting, with a 2026/07/17 PDUFA date, and traders suddenly have a clear catalyst calendar. Celcuity Inc. now plans a supplemental NDA based on the mutant‑cohort results, aiming to build a broad second‑line HR+/HER2‑ breast cancer franchise. That kind of multi‑setting opportunity is exactly what fuels sustained trading interest in CELC, especially while the chart is already trending higher.
More Breaking News
- BlackBerry Stock Jumps As QNX And Cash Flow Momentum Build
- RIVN Stock Slips As Wall Street And Weather Test Bull Case
- BTG Stock Dips As Sector Sentiment Softens On Downgrades
- SMMT Plunges As Summit Therapeutics Stock Sheds Over 27%
Conclusion
CELC is acting like a textbook catalyst runner: strong news, heavy attention, and a chart that confirms the story. Celcuity Inc. has moved gedatolisib from “promising” to “late‑stage winner” territory in HR+/HER2‑ advanced breast cancer, with Phase 3 VIKTORIA‑1 data that beat alpelisib plus fulvestrant on progression‑free survival and showed manageable safety. With Priority Review already in place for PIK3CA wild‑type patients and a 2026/07/17 PDUFA date circled, Celcuity Inc. is lining up multiple shots on goal via an sNDA for the mutant population.
Financially, CELC is still burning cash and posting steep losses, but it holds significant liquidity and the balance sheet gives the company time to execute its regulatory plan. That’s why the market is willing to pay a rich multiple today: traders are discounting tomorrow’s potential franchise revenues, not today’s income statement.
For active traders, the message is simple: respect the trend but never forget the risk. CELC is a high‑volatility biotech tied to a handful of regulatory decisions and commercial outcomes. As Tim Sykes likes to remind his students, “The rules are simple: cut losses quickly, stick to your plan, and never believe the hype — verify it on the chart.” As millionaire penny stock trader and teacher Tim Sykes, says, “It’s better to go home at zero than to go home in the red.”. CELC’s story is powerful, but trading it still demands discipline, a clear risk level, and a willingness to step aside if the price action cracks.
This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.
Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:
- Penny Stocks Trading Guide
- Best Penny Stocks Under $1 to Buy Today
- Top 8 Penny Stocks to Watch on Robinhood
Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:
Leave a reply